CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
Sapanisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02197572
NCT02197572Phase 1Completed
CompareCT.gov

A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors

Calithera Biosciences, Inc·interventional·Posted Jul 22, 2014·Updated Jan 23, 2023

In Brief

A Phase 1 clinical trial evaluating Sapanisertib for Advanced Solid Tumors. Completed, enrolled 44 participants across 5 sites.

Detailed Summary

The purpose of this study is to characterize the effect of a single dose of 40 mg sapanisertib (MLN0128) on the electrocardiographic QT/QTc interval in participants with advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 22, 2014
Enrollment StartSep 15, 2014
Primary CompletionJun 10, 2016
Study CompletionFeb 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.9 years ago

Interventions

Sapanisertibdrug

Sapanisertib capsules.